logo
Plus   Neg
Share
Email

Agilent Tech Settles Intellectual Property Case In China

Agilent Technologies Inc. (A) said that it reached agreement with China-based companies EChrom and Pannatek, as well as certain former Agilent employees, regarding an intellectual property dispute related to Agilent gas chromatography technology. Specific financial terms of the settlement were not disclosed.

EChrom and Pannatek admitted that - without Agilent's permission - they obtained from certain former Agilent employees, technical drawings and/or technical documents carrying Agilent trade secrets by violating the company's confidentiality requirements.

The two companies then used technologies that were identical to, or substantially similar to, Agilent's technical drawings and technical documents in the development and manufacture of their gas chromatograph products.

The settlement agreement requires the payment of damages to Agilent, destruction of all technical drawings and technical documents carrying any Agilent trade secrets.

The companies also agreed to cease the production and sale of products using any Agilent trade secrets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Back-to-school and college spending is projected to exceed the $100 billion mark for the first time ever ever despite the coronavirus pandemic, according to an annual survey by the National Retail Federation or NRF. The survey released by NRF and Prosper Insights & Analytics projects total spending for K-12 and college combined to reach $101.6 billion in 2020, up from last year's $80.7 billion. U.S. laboratory equipment maker Thermo Fisher Scientific Inc. (TMO) and Netherlands-based Qiagen N.V. (QGEN) announced Thursday that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of Qiagen. The... Morgan Stanley (MS) reported better-than-expected Q2 results, bolstered by strong trading revenues, amid the COVID-19 pandemic.
Follow RTT